Safety of AS03-adjuvanted influenza vaccines: A review of the evidence
Open Access
- 25 April 2019
- journal article
- review article
- Published by Elsevier BV in Vaccine
- Vol. 37 (23), 3006-3021
- https://doi.org/10.1016/j.vaccine.2019.04.048
Abstract
No abstract availableFunding Information
- GlaxoSmithKline Biologicals SA
This publication has 106 references indexed in Scilit:
- Long-term immunogenicity of an AS03-adjuvanted influenza A(H1N1)pdm09 vaccine in young and elderly adults: An observer-blind, randomized trialVaccine, 2013
- AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trialThe Lancet Infectious Diseases, 2013
- Risk of Fetal Death after Pandemic Influenza Virus Infection or VaccinationThe New England Journal of Medicine, 2013
- Immunogenicity Profile of a 3.75-μg Hemagglutinin Pandemic rH5N1 Split Virion AS03A-Adjuvanted Vaccine in Elderly Persons: A Randomized TrialThe Journal of Infectious Diseases, 2011
- Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunityVaccine, 2011
- Age-Specific Effectiveness of an Oil-in-Water Adjuvanted Pandemic (H1N1) 2009 Vaccine Against Confirmed Infection in High Risk Groups in EnglandThe Journal of Infectious Diseases, 2011
- H5N1 Influenza Vaccine Formulated with AS03A Induces Strong Cross-Reactive and Polyfunctional CD4 T-Cell ResponsesJournal of Clinical Immunology, 2010
- Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6–35 monthsVaccine, 2010
- Safety and Cross‐Reactive Immunogenicity of Candidate AS03‐Adjuvanted Prepandemic H5N1 Influenza Vaccines: A Randomized Controlled Phase 1/2 Trial in AdultsThe Journal of Infectious Diseases, 2010
- Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: Preliminary report of an observer-blind, randomised trialVaccine, 2010